The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist.
Duncia
J V
JV
DuPont Merck Pharmaceutical Company, Experimental Station, Wilmington, Delaware 19880-0402.
Carini
D J
DJ
Chiu
A T
AT
Johnson
A L
AL
Price
W A
WA
Wong
P C
PC
Wexler
R R
RR
Timmermans
P B
PB
D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D000818:Animals; D000959:Antihypertensive Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D001667:Binding, Competitive; D001713:Biphenyl Compounds / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical / Q000379:methods* / Q000639:trends; D006801:Humans; D007093:Imidazoles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D016234:Kallikrein-Kinin System / Q000187:drug effects; D019808:Losartan; D008956:Models, Chemical; D011817:Rabbits; D051381:Rats; D012084:Renin-Angiotensin System / Q000187:drug effects; D013777:Tetrazoles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use
D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D007093:Imidazoles; D013777:Tetrazoles; D000804:Angiotensin II; D019808:Losartan